Caris Life Sciences vs Fortrea
CAI and FTRE side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAI and FTRE compare
Caris Life Sciences is the larger company, worth 3.0 times as much as Fortrea ($5.6B against $1.9B).
Caris Life Sciences grew revenue faster over the last twelve months (61.5% versus −3.4% for Fortrea).
Caris Life Sciences keeps more of each dollar of sales as profit, with a net margin of 9.2% compared with −2.6% at Fortrea.
Caris Life Sciences scores higher on the StockData Score (7 against 4 for Fortrea), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAI | FTRE |
|---|---|---|
| Size and price | ||
| Market cap | $5.6B | $1.9B |
| Share price | $19.94 | $19.59 |
| Change, 1 year | −16.4% | 88.2% |
| Beta (5Y) | 2.53 | 1.30 |
| Employees | 1,846 | 14K |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 3 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.4× | 0.7× (better) |
| P/B | 8.8× | 3.6× (better) |
| EV/EBITDA | 36.5× | 29.8× (better) |
| P/FCF | 195× | 11.2× (better) |
| FCF yield | 0.51% | 8.9% (better) |
| Fair value | $10.35 | $12.57 |
| Margin of safety | −92.6% | −55.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 61.5% (better) | −3.4% |
| Profitability | ||
| Gross margin | – | 20.0% |
| Operating margin | 13.4% (better) | 0.48% |
| Net margin | 9.2% (better) | −2.6% |
| FCF margin | 2.8% | 6.3% (better) |
| Return on equity | 17.2% (better) | −12.3% |
| Return on invested capital | 26.8% (better) | 0.69% |
| Financial health | ||
| Debt / equity | 0.61 (better) | 1.98 |
| Net debt / EBITDA | 1.79 (better) | 9.12 |
| Interest coverage | 3.3× | – |
| Current ratio | 6.71 (better) | 0.97 |
| Altman Z-score | 4.73 (better) | 0.76 |
| Piotroski F-score | 6 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | 0.56% | – |
| Shareholder yield | 0.56% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 54.5% | 104% |
| Held by insiders | 64.1% | 3.9% |
| Insider net buying, 12 months | −$27.4M | −$4.7M (better) |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 11.3% | 9.2% |
Go deeper
- CAI stock overview
- CAI income statement
- CAI valuation and score
- FTRE stock overview
- FTRE income statement
- FTRE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.